Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change

Leadership Change - Trevi Therapeutics, Inc. appointed David Hastings as Chief Financial Officer, effective January 6, 2026, marking a significant leadership change as the company transitions into a more advanced development stage [2] - Hastings brings 25 years of financial leadership experience in public life sciences companies and has helped raise $2 billion in equity and debt financing, aligning with Trevi's growth strategy [2] Clinical Development - Trevi is preparing to request an End-of-Phase 2 meeting with the FDA in Q4 2025 for its lead program targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF), having completed key Phase 2 work [3] - The company expects to initiate a Phase 3 program in the first half of 2026, reinforcing its transition into this critical phase of development [3] Safety and Efficacy Studies - The ongoing Phase 1 TIDAL study in IPF patients has shown no safety signals, and a completed drug-drug interaction study confirmed that nalbuphine ER can be safely co-administered with standard antifibrotic therapies [4] - Trevi has presented topline Phase 2b CORAL data, enhancing clinical and investor visibility [4] Financial Position - As of the end of Q3 2025, Trevi Therapeutics reported a cash balance of $194.9 million, positioning the company well to capitalize on its clinical momentum [5] - The company is focused on developing Haduvio, an oral extended-release therapy for chronic cough across IPF, Non-IPF ILD, and refractory chronic cough [5]